Resource Summary Report

Generated by dkNET on Sep 6, 2026

HEC-1-A

RRID:CVCL_0293
Type: Cell Line

Proper Citation

RRID:CVCL_0293

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0293

Proper Citation: RRID:CVCL_0293

Description: Cell line HEC-1-A is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Type II endometrial adenocarcinoma

Defining Citation: PMID:327080, PMID:833871, PMID:2436984, PMID:3410349, PMID:3518877, PMID:4678779, PMID:7459858, PMID:10381137, PMID:12068308, PMID:12227503, PMID:12714694, PMID:12893190, PMID:15053063, PMID:15901131, PMID:20215515, PMID:20218740, PMID:22460905, PMID:22710073, PMID:25485619, PMID:25984343, PMID:28196595, PMID:30894373, PMID:31068700, PMID:31978347

Comments: Population: Japanese., Part of: PI3K genetic alteration cell panel (ATCC TCP-1028)., Part of: MD Anderson Cell Lines Project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: HEC-1-A

Synonyms: Hec-1-A, HEC-1A, HEC1-A, HEC1A, Hec1A

Cross References: BTO:BTO_0002960, CLO:CLO_0003674, EFO:EFO_0002191, MCCL:MCC:0000183, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ATCC:HTB-112, BCRC:60552, BioGRID_ORCS_Cell_line:421, BioSample:SAMN03471093, BioSample:SAMN03472456, BioSample:SAMN10988293, cancercelllines:CVCL_0293, CCRID:3101HUMTCHu149,

Cell_Model_Passport:SIDM00595, ChEMBL-Cells:CHEMBL4295424, ChEMBL-Targets:CHEMBL4296424, CLS:305077, Cosmic:713474, Cosmic:713494, Cosmic:724853, Cosmic:809130, Cosmic:846177, Cosmic:871552, Cosmic:889115, Cosmic:1007160, Cosmic:1066222, Cosmic:1177620, Cosmic:1177685, Cosmic:1576457, Cosmic:1594188, Cosmic:1622896, Cosmic:2030464, Cosmic:2301550, Cosmic:2464665, Cosmic:2646619, DepMap:ACH-000954, EGA:EGAS00001000610, GEO:GSM844555, GEO:GSM844556, GEO:GSM887069, GEO:GSM888139, IARC_TP53:1110, IGRhCellID:HEC1A, JCRB:JCRB1117, JCRB:NIHS0388, LiGeA:CCLE_208, PharmacoDB:HEC1A_524_2019, Progenetix:CVCL_0293, PubChem_Cell_line:CVCL_0293, Wikidata:Q54882246

ID: CVCL_0293

Hierarchy: cvcl_1274

Record Creation Time: 20220427T220324+0000

Record Last Update: 20260905T180230+0000

Ratings and Alerts

No rating or validation information has been found for HEC-1-A.

Warning: Discontinued: JCRB; NIHS0388
Population: Japanese., Part of: PI3K genetic alteration cell panel (ATCC TCP-1028)., Part of: MD Anderson Cell Lines Project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 398 mentions in open access literature.

Listed below are recent publications. The full list is available at dkNET .

Huang TT, et al. (2026) DHX9 inhibition enhances paclitaxel sensitivity by inducing mitotic failure in ovarian and endometrial cancers. Molecular cancer therapeutics.

Peng J, et al. (2026) CBLC-mediated ubiquitination stabilizes METTL1, enhances N7-methylguanosine modification of ESRRA, and promotes the progression of endometrial cancer. International journal of biological macromolecules, 369, 152809.

Resch V, et al. (2026) Targeting Steroid-Metabolizing Enzymes with 15?-Substituted Estrone Analogues: Dual Discovery of AKR1C2/17?-HSD1 Inhibitors and a Fluorescent 17 ?-HSD1 Ligand. Cancers, 18(12).

Santiappillai NT, et al. (2025) Pathway metabolite ratios reveal distinctive glutamine metabolism in a subset of proliferating cells. Molecular systems biology, 21(8), 983.

Nelson BE, et al. (2025) Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi-NT in Patients with Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(18), 3864.

Blinkiewicz PV, et al. (2025) Colorectal cancer-associated PCBP1 mutations disrupt protein stability in a dominant negative manner. bioRxiv : the preprint server for biology.

Yu H, et al. (2025) Assessment of NUDT5 in Endometrial Carcinoma: Functional Insights, Prognostic and Therapeutic Implications. Biomedicines, 13(5).

Lindén M, et al. (2025) FET fusion oncoproteins enrich SWI/SNF complex subtypes and interaction partners. Cellular & molecular biology letters, 30(1), 107.

Aljardali MW, et al. (2024) Nucleolar Localization of the RNA Helicase DDX21 Predicts Survival Outcomes in Gynecologic Cancers. Cancer research communications, 4(6), 1495.

Gjorgoska M, et al. (2024) Pre-receptor regulation of 11-oxyandrogens differs between normal and cancerous endometrium and across endometrial cancer grades and molecular subtypes. Frontiers in endocrinology, 15, 1404804.

Dissanayake K, et al. (2024) Do extracellular vesicles have specific target cells?; Extracellular vesicle mediated embryo maternal communication. Frontiers in molecular biosciences, 11, 1415909.

Okumura T, et al. (2024) Rel Family Transcription Factor NFAT5 Upregulates COX2 via HIF-1? Activity in Ishikawa and HEC1a Cells. International journal of molecular sciences, 25(7).

Meril S, et al. (2024) Loss of EIF4G2 mediates aggressiveness in distinct human endometrial cancer subpopulations with poor survival outcome in patients. Oncogene.

Joseph R, et al. (2024) EphA2- and HDAC-Targeted Combination Therapy in Endometrial Cancer. International journal of molecular sciences, 25(2).

Tang S, et al. (2023) ERR? Up-Regulates Invadopodia Formation by Targeting HMGCS1 to Promote Endometrial Cancer Invasion and Metastasis. International journal of molecular sciences, 24(4).

Su Y, et al. (2023) Ubiquitin-specific peptidase 14 maintains estrogen receptor ? stability via its deubiquitination activity in endometrial cancer. The Journal of biological chemistry, 299(1), 102734.

Zhao X, et al. (2023) Effects of RFRP?3 on an ovariectomized estrogen?primed rat model and HEC?1A human endometrial carcinoma cells. Experimental and therapeutic medicine, 25(2), 76.

Ruan GY, et al. (2023) An integrated approach of network pharmacology, molecular docking, and experimental verification uncovers kaempferol as the effective modulator of HSD17B1 for treatment of endometrial cancer. Journal of translational medicine, 21(1), 204.

Niu L, et al. (2023) Identification and validation of oxeiptosis-associated lncRNAs and prognosis-related signature genes to predict the immune status in uterine corpus endometrial carcinoma. Aging, 15(10), 4236.

Pandur E, et al. (2023) The Role of Fractalkine in the Regulation of Endometrial Iron Metabolism in Iron Deficiency. International journal of molecular sciences, 24(12).